Prothena (NASDAQ:PRTA) posted its earnings results on Tuesday. The biotechnology company reported ($0.62) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.05) by $0.43, Fidelity Earnings reports. The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.26 million. Prothena had a negative net margin of 18,276.97% and a negative return on equity of 41.75%.
Shares of PRTA opened at $13.02 on Thursday. Prothena has a one year low of $10.43 and a one year high of $59.50. The stock has a market capitalization of $510.31 million, a price-to-earnings ratio of -3.20 and a beta of 2.63.
A number of analysts have recently weighed in on the stock. BidaskClub upgraded shares of Prothena from a “hold” rating to a “buy” rating in a report on Wednesday, August 15th. Zacks Investment Research upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Friday, August 10th. Cantor Fitzgerald restated a “buy” rating and issued a $18.00 price objective on shares of Prothena in a report on Wednesday, August 8th. Finally, ValuEngine upgraded shares of Prothena from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 2nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $36.67.
ILLEGAL ACTIVITY NOTICE: “Prothena (PRTA) Releases Earnings Results, Beats Expectations By $0.43 EPS” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/08/prothena-prta-releases-earnings-results-beats-expectations-by-0-43-eps.html.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
Further Reading: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.